Posted on: 16 February 2018

(a) Cyclotek Melbourne Pty Ltd is issued with a Licence to Manufacture Therapeutic Goods by the TGA – Feb 2018 and commenced operations in April 2018.

(b) Cyclotek Queensland Pty Ltd validates the fluorinated DCFPyL, PSMA agent for Prostate Imaging. To be used within our Clinical Trial. Radiologists and Nuclear Medicine Physicians have requested access via the Special Access Scheme.

(c) Cyclotek Queensland Pty Ltd validates 18F Florbetaben to support pharmaceutical sponsored clinical trials as a bio-market for therapeutic trials and supporting local researchers with their respective Investigator Sponsored Studies.

(d) Cyclotek NSW Pty Ltd acquires the business of PETTECH Solutions Pty Ltd with a commencement date of 2 January 2019. This acquisition enables the business to further develop  PET Radiopharmaceuticals into the NSW marketplace.

(e) Cyclotek (Aust) Pty Ltd validates 18F F-AraG on behalf of Telix Pharmaceuticals Ltd. 18F F-AraG hones in on and images activated T cells that are critical to any immune modulated therapy.

[contact-form-7 id=”714″ title=”Update Form”]